Capricor Therapeutics, Inc. (CAPR) Stock: Is This Biotech Stock Worth Your Attention?


Capricor Therapeutics, Inc. (CAPR) is headed up in the market today. The stock, focused in the biotechnology sector, is presently priced at $0.53 after a move up of 12.53% so far today. When it comes to biotech companies, there are a number of factors that have the ability to lead to price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to CAPR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-21-19 07:40AM Capricor Therapeutics, Inc. (NASDAQ:CAPR): Commentary On Fundamentals
Feb-06-19 07:00AM Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
Jan-24-19 09:30AM 4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)
07:00AM Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricors Novel Cell Therapy
Jan-22-19 07:00AM Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA

Nonetheless, when making a decision to invest, investors should focus on far more than news, especially in the highly speculative biotechnology industry. Here’s what’s going on with Capricor Therapeutics, Inc..

Recent Movement From CAPR

Although a move up on a single session, like the move that we’re seeing from Capricor Therapeutics, Inc. may cause excitement in some investors, that by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s always a good idea to dig into trends experienced by the stock for a period longer than a single trading session. When it comes to CAPR, here are the trends that we have seen:

  • Past Seven Days – Over the last five trading sessions, CAPR has seen a change in price that amounts to 18.62%.
  • Monthly – The monthly ROI from Capricor Therapeutics, Inc. has been 20.45%.
  • Past Quarter – Over the past 3 months, the stock has produced a ROI that comes to -5.36%
  • Bi-Annually – In the past 6 months, we’ve seen a change that equates to -55.08% from the company.
  • This Year So Far – Since the the last trading session of last year CAPR has resulted in a return on investment of 29.27%.
  • Full Year – Finally, in the last full year, investors have seen movement in the amount of -70.39% from CAPR. In this period, the stock has traded at a high price of -72.82% and a low price of 70.97%.

Key Ratios

Looking at a few ratios associated with a stock can give prospective traders an understanding of how dangerous and/or potentially profitable a stock pick might be. Here are some of the important ratios to consider when digging into CAPR.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the value of the stock is going to fall. Across the sector, biotech stocks tend to come with a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, as it relates to Capricor Therapeutics, Inc., the stock’s short ratio clocks in at 2.18.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can pay for its debts when they mature with only current assets or quick assets. Because many biotech several companies are reliant on continued investor support, the current and quick ratios can look damning. However, some gems in the biotech space do have positive quick and current ratios. When it comes to CAPR, the quick and current ratios come to 6.10 and 6.10 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets that are owned by the company. as it relates to Capricor Therapeutics, Inc., the book to share value ratio equates to 0.23.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Many early stage biotech companies struggle to keep cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to think about. In the case of CAPR, the cash to share value ratio comes to 0.34.

Analyst Opinions Of Capricor Therapeutics, Inc.

While it’s never a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to use their analysis in order to validate your own due diligence before making investment decisions in the biotechnology space. Below you’ll find|Here are} the most recent moves that we have seen from analysts as it relates to CAPR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-26-18 Downgrade Maxim Group Buy → Hold
Jan-26-18 Reiterated H.C. Wainwright Buy $6.50 → $8.60
Sep-15-17 Reiterated H.C. Wainwright Buy $2.15 → $6.50
Feb-13-17 Resumed Rodman & Renshaw Buy $14
Jul-06-16 Resumed H.C. Wainwright Buy $13

What Institutions And Insiders Think Of Capricor Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CAPR, here’s what we’re seeing:

  • Institutions – Currently, institutional investors own 5.40% of CAPR. Nonetheless, it is worth noting that institutional ownership has changed in the amount of -24.21% over the last quarter.
  • Insider Moves – as it relates to insiders, those close to the situation currently own 35.68% of the company. Their ownership of the company has moved 0.00% throughout the last 3 months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 30.55M shares of Capricor Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CAPR has a float of 19.98M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CAPR, the short percent of the float is 3.39%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.50. In the current quarter, analysts see the company producing earnings in the amount of $-0.16. Over the last 5 years, CAPR has generated revenue in the amount of $7.00% with earnings coming in at 19.50%. On a quarter over quarter basis, earnings have seen movement of -15.50% and revenue has seen movement of -33.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, based on what I am, I can learn by myself. However, I was created by a human and human beings actually play an important part in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I learn much faster when I have the help of a teacher. If you would to help me learn something, I would love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at information? If so, leave a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here